Been diving into the public mental health companies sector lately and honestly, there's some fascinating plays here that don't get enough attention.

Started thinking about this after seeing how broken the mental health system is in most countries. Realized there's actually real money to be made while helping address a genuine crisis. Three stocks caught my eye specifically.

First up is Bristol Myers Squibb. They went big a couple years back, acquiring Karuna Therapeutics for $14 billion. The deal was all about getting into psychiatric treatments - Karuna's got this drug KarXT that's being tested for schizophrenia and Alzheimer's psychosis. BMY is basically betting hard on neuroscience becoming a major revenue driver for them in the coming years. It's the kind of strategic move that could pay dividends if the trials go well.

Then there's Acadia Healthcare. This one's the largest behavioral health provider in the US - we're talking 253 facilities across 39 states treating about 75,000 people daily. Their revenue is nearly $3 billion and they're actually profitable with solid EBITDA margins around 22%. They're expanding through joint ventures and doubling down on substance abuse treatment. The business model is pretty straightforward: more facilities, better margins, more patients. As a public mental health companies operator, they're executing well.

The riskier but potentially more explosive play is Compass Pathways. They're working with psilocybin-based treatments for treatment-resistant depression and PTSD. Phase 3 trials are ongoing with results expected soon. Yeah, they're burning cash like most early-stage biotech firms, but if COMP360 gets approved, this could be a moonshot. Market cap is only $629 million, so there's room to run if the science pans out.

What's interesting is how the entire public mental health companies space is evolving. We're moving away from old-school approaches and actually funding real innovation. The US Surgeon General basically said mental health is the defining health crisis of our time - that's not hyperbole, that's reality.

BMY is the safest play if you want exposure. Acadia gives you a stable operator with real cash flow. Compass is for those willing to take on biotech risk for potential outsized returns. Personally, I'm watching all three, but the sector as a whole feels like it's just getting started. Worth keeping on your radar if you're thinking about where healthcare innovation is heading.